Jiangsu Nhwa Pharmaceutical Management

Management criteria checks 3/4

Jiangsu Nhwa Pharmaceutical's CEO is Jiaquan Sun, appointed in May 2013, has a tenure of 11.08 years. directly owns 0.071% of the company’s shares, worth CN¥17.15M. The average tenure of the management team and the board of directors is 11.1 years and 17.2 years respectively.

Key information

Jiaquan Sun

Chief executive officer

CN¥4.8m

Total compensation

CEO salary percentage	n/a
CEO tenure	11.1yrs
CEO ownership	0.07%
Management average tenure	11.1yrs
Board average tenure	17.2yrs

Recent management updates

Recent updates

CEO

Jiaquan Sun (48 yo)

11.1yrs

Tenure

CN¥4,800,000

Compensation

Mr. Jiaquan Sun has been General Manager at Jiangsu Nhwa Pharmaceutical Co., Ltd. since May 31, 2013 and has been its Non-Independent Director since April 1, 2019. Mr. Sun serves as General Manager of Jian...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jiaquan Sun	GM & Non-Independent Director	11.1yrs	CN¥4.80m	0.071% CN¥ 17.2m
Gangsheng Li	Chief Financial Officer	1.7yrs	CN¥633.60k	no data
Qing Fu	Deputy GM & Non-Independent Director	11.1yrs	CN¥200.00k	3.96% CN¥ 963.1m
Zengliang Chen	Deputy GM & Non-Independent Director	11.1yrs	CN¥200.00k	3.96% CN¥ 963.1m
Ziliang Yang	Deputy GM & Non-Independent Director	11.1yrs	CN¥200.00k	3.72% CN¥ 905.3m
Bao Zhou Duan	Deputy GM & Secretary	11.1yrs	CN¥413.70k	0.0053% CN¥ 1.3m

11.1yrs

Average Tenure

59yo

Average Age

Experienced Management: 002262's management team is seasoned and experienced (11.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jiaquan Sun	GM & Non-Independent Director	14.1yrs	CN¥4.80m	0.071% CN¥ 17.2m
Qing Fu	Deputy GM & Non-Independent Director	17.2yrs	CN¥200.00k	3.96% CN¥ 963.1m
Zengliang Chen	Deputy GM & Non-Independent Director	17.2yrs	CN¥200.00k	3.96% CN¥ 963.1m
Ziliang Yang	Deputy GM & Non-Independent Director	17.2yrs	CN¥200.00k	3.72% CN¥ 905.3m
Pengsheng Sun	Non-Independent Chairman of the Board	17.2yrs	CN¥250.00k	4.91% CN¥ 1.2b
Guangji Wang	Independent Director	5.3yrs	CN¥50.00k	no data
Yu Lan Li	Independent Director	2.2yrs	CN¥50.00k	no data
Fengshou Wang	Chairman of the Supervisory Board	17.2yrs	no data	no data
Xinglei Jia	Member of the Supervisory Board	17.2yrs	no data	no data
Xiao Chen Qian	Employee Representative Member of Supervisory Board	17.2yrs	no data	no data
Xiaoxing Yin	Independent Director	2.2yrs	CN¥50.00k	no data
Guoxiang Chen	Independent Director	2.2yrs	CN¥50.00k	no data

17.2yrs

Average Tenure

61yo

Average Age

Experienced Board: 002262's board of directors are seasoned and experienced ( 17.2 years average tenure).

Jiangsu Nhwa Pharmaceutical Management

Management criteria checks 3/4

Key information

Recent management updates

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 24, 2024

High number of new directors

Jiangsu Nhwa Pharmaceutical Co., LTD Approves the Election of Chen Guoxiang and Li Yulan as Independent Directors

Insufficient new directors

Insufficient new directors

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 29, 2022

Recent updates

Now 21% overvalued

Full year 2023 earnings released: EPS: CN¥1.03 (vs CN¥0.89 in FY 2022)

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 24, 2024

Investor sentiment deteriorates as stock falls 17%

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.34 (vs CN¥0.30 in 3Q 2022)

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: CN¥0.31 (vs CN¥0.25 in 2Q 2022)

Jiangsu Nhwa Pharmaceutical Co., LTD to Report First Half, 2023 Results on Jul 31, 2023

Jiangsu Nhwa Pharmaceutical Co., Ltd. Receives Formal Approval from the National Medical Products Administration for OLINVYK

Full year 2022 earnings released: EPS: CN¥0.89 (vs CN¥0.79 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.30 (vs CN¥0.26 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.24 in 2Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.24 in 2Q 2021)

High number of new directors

Jiangsu Nhwa Pharmaceutical Co., LTD Approves the Election of Chen Guoxiang and Li Yulan as Independent Directors

First quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.17 in 1Q 2021)

Insufficient new directors

Insufficient new directors

Full year 2021 earnings released: EPS: CN¥0.79 (vs CN¥0.72 in FY 2020)

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 29, 2022

Jiangsu Nhwa Pharmaceutical Co., LTD, Annual General Meeting, Apr 29, 2022

Jiangsu Nhwa Pharmaceutical Co., Ltd Proposes Cash Dividend for 2021

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.21 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.24 (vs CN¥0.21 in 2Q 2020)

Jiangsu Nhwa Pharmaceutical Co., Ltd Announces 2020 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 02 June 2021

First quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.14 in 1Q 2020)

New 90-day low: CN¥13.53

Full year 2020 earnings released: EPS CN¥0.72 (vs CN¥0.66 in FY 2019)

Revenue beats expectations

New 90-day low: CN¥14.10

Investor sentiment deteriorated over the past week

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Fiscal Year 2020 Results on Mar 12, 2021

New 90-day low: CN¥15.46

New 90-day high: CN¥18.50

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

Jiangsu Nhwa Pharmaceutical Co., LTD to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: CN¥15.34

New 90-day low - CN¥15.61

New 90-day high - CN¥18.57

Jiangsu Nhwa Pharmaceutical Co., LTD to Report First Half, 2020 Results on Jul 31, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age